TrialBeacon
USClinicalTrials.govClinical trialRecruiting

Longitudinal Studies of Patient With FPDMM

Open the official recordBack

Official record

Identifier
NCT03854318
Recruiting locations

country

United States
Interventions studied
Not provided in the official record
Lead sponsor
National Human Genome Research Institute (NHGRI)
Target enrolment
1000 participants
Study type
OBSERVATIONAL
Phase
Not provided in the official record
Status
Recruiting
First posted
Feb 26, 2019
Last updated on the registry
Jul 31, 2026
Age
1 Day – 100 Years
Sex
ALL
Study contact
The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.
Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

* INCLUSION CRITIERIA:

Patients enrolled in this protocol will have been referred with a known or suspected variant in the RUNX1 gene. Patients with suspected RUNX1 variants are those with clinical features of FPD but who have not been tested for RUNX1, or who were negative on standard testing. The Principal Investigator, along with consulting specialists, will review the medical records of prospective patients and offer enrollment based upon the potential to help the individual, to learn from the patient, or to initiate clinical or basic research suggested by the patient's workup. Persons interested in participation may be given a screening questionnaire to determine eligibility. The questions about hematologic manifestations in the screening questionnaire are important to help us determine if RUNX1 variants are likely to be pathogenic, or if there is a high clinical suspicion of RUNX1 (abnormal platelets, bleeding, bruising, leukemia etc.). Unaffected family members may be asked to enroll in the study to provide specimens (saliva, blood, skin) for genetic testing, next-generation sequencing, and other related studies. Enrolled subjects can be any sex and any age. There are no upper or lower age restrictions on this study.

EXCLUSION CRITIERIA:

There are no exclusionary criteria.
Indexed under
Leukemia

This site does not provide medical advice

TrialBeacon only aggregates links to publicly available official information. It does not recommend, rank or evaluate any treatment, trial or medicine, and nothing here implies suitability for any individual. Please discuss anything you find with your treating doctor, and always rely on the original official page — records change over time. Full disclaimer.